Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

28.90
-1.0500-3.51%
Post-market: 28.900.00000.00%17:57 EDT
Volume:909.35K
Turnover:26.36M
Market Cap:1.66B
PE:-12.79
High:30.46
Open:29.62
Low:28.37
Close:29.95
52wk High:40.37
52wk Low:4.30
Shares:57.37M
Float Shares:48.42M
Volume Ratio:0.46
T/O Rate:1.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2601
EPS(LYR):-2.2601
ROE:-46.56%
ROA:-25.68%
PB:5.42
PE(LYR):-12.79

Loading ...

Capricor Exec Says FDA Indicated It Would Be Class Two Resubmission, Which Is About Six Months

THOMSON REUTERS
·
Dec 03, 2025

Capricor Exec Says Deramiocel Can Be Used With Any Therapeutics Currently Approved, Available or Under Clinical Development

THOMSON REUTERS
·
Dec 03, 2025

Capricor Exec Says Co Will Certainly Ask for Label for Skeletal Muscle Myopathy Based on Data

THOMSON REUTERS
·
Dec 03, 2025

Capricor Shares up 15% Premarket After Co's Muscle Disorder Cell Therapy Meets Late-Stage Trial Goal

THOMSON REUTERS
·
Dec 03, 2025

BRIEF-Capricor Therapeutics Announces Positive Topline Results From Pivotal Phase 3 Hope-3 Study

Reuters
·
Dec 03, 2025

Capricor eyes US nod for Duchenne cell therapy after success in key study

Reuters
·
Dec 03, 2025

Capricor Therapeutics' muscle disorder cell therapy succeeds in late-stage study

Reuters
·
Dec 03, 2025

Capricor Therapeutics Reports Positive Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy

Reuters
·
Dec 03, 2025

Capricor Therapeutics Inc - Deramiocel Maintains Favorable Safety Profile

THOMSON REUTERS
·
Dec 03, 2025

Capricor Therapeutics Announces Positive Topline Results From Pivotal Phase 3 Hope-3 Study of Deramiocel in Duchenne Muscular Dystrophy

THOMSON REUTERS
·
Dec 03, 2025

Capricor Therapeutics Inc - Company to Submit Response to Complete Response Letter

THOMSON REUTERS
·
Dec 03, 2025

Capricor Therapeutics Inc - Phase 3 Study Meets Primary and Secondary Endpoints

THOMSON REUTERS
·
Dec 03, 2025

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:15 AM

Reuters
·
Dec 03, 2025

Capricor Therapeutics (CAPR) Receives a Buy from Roth MKM

TIPRANKS
·
Nov 25, 2025

Martin Shkreli Takes Aim At Capricor — Stock Sinks

Benzinga
·
Nov 25, 2025

Capricor Therapeutics (CAPR) Stock Is Sliding Today: Should Retail Investors Be Worried?

Benzinga
·
Nov 24, 2025

Capricor presents data on framework for loading oligonucleotides into exosomes

TIPRANKS
·
Nov 24, 2025

Capricor Therapeutics Unveils Scalable Method for Loading Therapeutic Oligonucleotides into Exosomes

Reuters
·
Nov 24, 2025

Capricor Therapeutics Q3 EPS USD -0.54

Reuters
·
Nov 20, 2025

Capricor Therapeutics’ HOPE-3 Trial: A Pivotal Catalyst for Future Success

TIPRANKS
·
Nov 13, 2025